Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma

Xiangxuan Zhao, William M. Puszyk, Zaiming Lu, David A. Ostrov, Thomas J. George, Keith D Robertson, Chen Liu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Despite much effort, pancreatic cancer survival rates are still dismally low. Novel therapeutics may hold the key to improving survival. YM155 is a small molecule inhibitor that has shown antitumor activity in a number of cancers by reducing the expression of survivin. The aim of our study is to understand the mechanisms by which YM155 functions in pancreatic cancer cells. We established the antitumor effect of YM155 with in vitro studies in cultured cells, and in vivo studies using a mouse xenograft model. Our data demonstrated that YM155 reduced the expression of survivin; however, downregulation of survivin itself is insufficient to induce apoptosis in pancreatic cancer cells. We showed for the first time that treatment with YM155 increased death receptor 5 (DR5) expression in pancreatic cancer cells. We found that YM155 induced apoptosis by broad-spectrum inhibition of IAP family member proteins (e.g., CIAP1/2 and FLIP) and induced proapoptotic Bak protein upregulation and activation; the antitumor effect of YM155 treatment with either the DR5 agonist lexatumumab or gemcitabine on pancreatic cancer cells was synergistic. Our data also revealed that YM155 inhibits tumor growth in vivo, without apparent toxicity to the noncancerous human pancreatic ductal epithelial cell line. Together, these findings suggest that YM155 could be a novel therapeutic agent for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)80-89
Number of pages10
JournalMolecular Cancer Therapeutics
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

TNF-Related Apoptosis-Inducing Ligand Receptors
Pancreatic Neoplasms
Apoptosis
Drug Therapy
gemcitabine
bcl-2 Homologous Antagonist-Killer Protein
Therapeutics
Heterografts
Pancreatic Carcinoma
Cultured Cells
Neoplasms
Up-Regulation
Down-Regulation
Survival Rate
Epithelial Cells
Cell Line
Survival
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. / Zhao, Xiangxuan; Puszyk, William M.; Lu, Zaiming; Ostrov, David A.; George, Thomas J.; Robertson, Keith D; Liu, Chen.

In: Molecular Cancer Therapeutics, Vol. 14, No. 1, 01.01.2015, p. 80-89.

Research output: Contribution to journalArticle

Zhao, Xiangxuan ; Puszyk, William M. ; Lu, Zaiming ; Ostrov, David A. ; George, Thomas J. ; Robertson, Keith D ; Liu, Chen. / Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 1. pp. 80-89.
@article{1836550577024b1398bbc0ec11f9012a,
title = "Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma",
abstract = "Despite much effort, pancreatic cancer survival rates are still dismally low. Novel therapeutics may hold the key to improving survival. YM155 is a small molecule inhibitor that has shown antitumor activity in a number of cancers by reducing the expression of survivin. The aim of our study is to understand the mechanisms by which YM155 functions in pancreatic cancer cells. We established the antitumor effect of YM155 with in vitro studies in cultured cells, and in vivo studies using a mouse xenograft model. Our data demonstrated that YM155 reduced the expression of survivin; however, downregulation of survivin itself is insufficient to induce apoptosis in pancreatic cancer cells. We showed for the first time that treatment with YM155 increased death receptor 5 (DR5) expression in pancreatic cancer cells. We found that YM155 induced apoptosis by broad-spectrum inhibition of IAP family member proteins (e.g., CIAP1/2 and FLIP) and induced proapoptotic Bak protein upregulation and activation; the antitumor effect of YM155 treatment with either the DR5 agonist lexatumumab or gemcitabine on pancreatic cancer cells was synergistic. Our data also revealed that YM155 inhibits tumor growth in vivo, without apparent toxicity to the noncancerous human pancreatic ductal epithelial cell line. Together, these findings suggest that YM155 could be a novel therapeutic agent for pancreatic cancer.",
author = "Xiangxuan Zhao and Puszyk, {William M.} and Zaiming Lu and Ostrov, {David A.} and George, {Thomas J.} and Robertson, {Keith D} and Chen Liu",
year = "2015",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-14-0229",
language = "English (US)",
volume = "14",
pages = "80--89",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma

AU - Zhao, Xiangxuan

AU - Puszyk, William M.

AU - Lu, Zaiming

AU - Ostrov, David A.

AU - George, Thomas J.

AU - Robertson, Keith D

AU - Liu, Chen

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Despite much effort, pancreatic cancer survival rates are still dismally low. Novel therapeutics may hold the key to improving survival. YM155 is a small molecule inhibitor that has shown antitumor activity in a number of cancers by reducing the expression of survivin. The aim of our study is to understand the mechanisms by which YM155 functions in pancreatic cancer cells. We established the antitumor effect of YM155 with in vitro studies in cultured cells, and in vivo studies using a mouse xenograft model. Our data demonstrated that YM155 reduced the expression of survivin; however, downregulation of survivin itself is insufficient to induce apoptosis in pancreatic cancer cells. We showed for the first time that treatment with YM155 increased death receptor 5 (DR5) expression in pancreatic cancer cells. We found that YM155 induced apoptosis by broad-spectrum inhibition of IAP family member proteins (e.g., CIAP1/2 and FLIP) and induced proapoptotic Bak protein upregulation and activation; the antitumor effect of YM155 treatment with either the DR5 agonist lexatumumab or gemcitabine on pancreatic cancer cells was synergistic. Our data also revealed that YM155 inhibits tumor growth in vivo, without apparent toxicity to the noncancerous human pancreatic ductal epithelial cell line. Together, these findings suggest that YM155 could be a novel therapeutic agent for pancreatic cancer.

AB - Despite much effort, pancreatic cancer survival rates are still dismally low. Novel therapeutics may hold the key to improving survival. YM155 is a small molecule inhibitor that has shown antitumor activity in a number of cancers by reducing the expression of survivin. The aim of our study is to understand the mechanisms by which YM155 functions in pancreatic cancer cells. We established the antitumor effect of YM155 with in vitro studies in cultured cells, and in vivo studies using a mouse xenograft model. Our data demonstrated that YM155 reduced the expression of survivin; however, downregulation of survivin itself is insufficient to induce apoptosis in pancreatic cancer cells. We showed for the first time that treatment with YM155 increased death receptor 5 (DR5) expression in pancreatic cancer cells. We found that YM155 induced apoptosis by broad-spectrum inhibition of IAP family member proteins (e.g., CIAP1/2 and FLIP) and induced proapoptotic Bak protein upregulation and activation; the antitumor effect of YM155 treatment with either the DR5 agonist lexatumumab or gemcitabine on pancreatic cancer cells was synergistic. Our data also revealed that YM155 inhibits tumor growth in vivo, without apparent toxicity to the noncancerous human pancreatic ductal epithelial cell line. Together, these findings suggest that YM155 could be a novel therapeutic agent for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84961372185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961372185&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-14-0229

DO - 10.1158/1535-7163.MCT-14-0229

M3 - Article

C2 - 25344582

AN - SCOPUS:84961372185

VL - 14

SP - 80

EP - 89

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -